Getting Ugly for CGCAnd with Canopy cultivating at 29,920 KGs and selling 13,237 KGs they effectively added 16,683 KGs another full Q plus of sales to already a large inventory base. Sales down in a growth market this Q, and down in the present June 30, 2020 Q significantly. Most concerning is the drop in Rec dried sales by $20 million QoQ to the second lowest Q since adult rec. Dried flower is 45-55% of mature markets. This is a bad segment to be losing share in. 5.75 Quarters of inventory post write down. Harvest KG versus Sold KG was 14,256 KGs added to inventory for the Q. They still have too much production capacity IMO, especially when you consider they are to purchase minimum amounts from PharmHouse JV. Based on their Conference Call they are chasing the puck versus being where the puck is going. $843,275 pre tax charges for the Companys restructuring actions and other impairments. Sales: 13% decrease from the previous quarter or $16 million. They fully gave back the growth adjusted for provisions from last Q and then some. Sales for next Q look to be a further decline as their quarter to date trailing six month data indicates Rec sales were $50 million before excise tax versus $69 million last Q, a decrease of $19 million or -28%. Retailers not reordering product is a BIG BIG ISSUE. Perhaps part of it is a function of provinces cutting down inventory ordering per cycle as result of covid. But that would not have made much a difference, as that impacted two of 12 weeks. Medical had a $2.1 million increase (+6%) to $35.6 million with $0.1 million increase from Canadian and +$2.0 million (+11%) in International. Other Sales were down $3.6 million or -11% to $29.7 million as the increase in the last Q was largely Storz and Bickell holiday season. They sold 9,258 KGs in rec market down 16% or 1,722 KGs. Rec dried saw a $20 million decrease QoQ to $49 million, giving back last Q $10 million increase and more. Rec dried was the second lowest of any Q since legalization. Dried is such an important part of the market, even post 2.0. Oil evidenced a $1.5 million increase, but at 2% of sales for 2.0, oil 1.0 must have declined. I am concerned about their cost per gram going forward. If I take production costs and remove a 50% factor for Other Income from CoGS, they have a $4.54 adjusted cost per gram. And a range for the fiscal period of $3.66-$5.52 adjusted cost per gram. With revenue per gram continually compressing from value offerings, CGC reducing yield, this could get ugly. Restructuring Expenses: Add $99 million in tax recovery and you get a Net Income of negative $1.3 BILLION versus negative $124 million last Q. -$632 million for asset impairment. $563 million was $335 PPE and $193 million G/I -$58 million Loss from equity method investment Other Income and Expenses were negative $376 million for the Q. No Q was broken out. Harvests dropped 4,040 kgs -14% to 25,880 KGs Sales dropped 1,613 KGs -12% to 11,624 kgs They added more than one Q of sales to their considerable inventory pile. Sales took a hard turn down and would appear that Q1 F2021 are not fairing much better. The drop in recreational dried is very big issue. They did not have the right mix of high THC in C2019. Now they do not have the right mix of value brand, which also has to be high THC. I am concerned about their cost to grow SALEABLE flower. They still are producing far more than they can sell in Canada. Klein has his work cut out for him. He is not a stranger to Canopy as he was their Chairman for over a year. Copied from TheCannalysts